Microbiome and Checkpoint Inhibitors in Hepatocellular Carcinoma: Mechanistic Review
This narrative review synthesizes preclinical and emerging clinical evidence on how the gut microbiome modulates checkpoint inhibitor response in hepatocellular carcinoma, without establishing direct causality or clinical efficacy of microbiome-targeted interventions.
| Population | Patients with advanced hepatocellular carcinoma in the context of cirrhosis or chronic liver disease |
|---|---|
| Intervention | Gut microbiome modulation (biological mechanisms discussed: dysbiosis, bacterial translocation, microbial metabolites, FMT) |
| Comparator | null |
| Outcome | Response to immune checkpoint inhibitors in HCC; Intestinal permeability and bacterial translocation in murine HCC models; Myeloid-derived suppressor cell expansion and CD8+ T cell depletion in preclinical models; Akkermansia muciniphila restoration and hepatic inflammation in preclinical models; Overall survival in advanced HCC with ICI |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Response to immune checkpoint inhibitors in HCC | No quantitative estimate available; narrative synthesis only | — | Very low | — | |
| Intestinal permeability and bacterial translocation in murine HCC models | Preclinical: FMT from HCC patients to germ-free mice induced barrier disruption and hepatocarcinogenesis; in the CI reported | — | Very low | — | 2 studies |
| Myeloid-derived suppressor cell expansion and CD8+ T cell depletion in preclinical models | Preclinical: TLR4-dependent; in the quantitative CI reported | — | Very low | — | 1 studies |
| Akkermansia muciniphila restoration and hepatic inflammation in preclinical models | Preclinical: barrier function improvement and attenuation of hepatic inflammation and fibrosis; in the CI reported | — | Very low | — | 1 studies |
| Overall survival in advanced HCC with ICI | Not reported for microbiome-ICI interaction in HCC | — | Very low | — |
Context
Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide, with a 5-year overall survival below 30%. Immune checkpoint inhibitors (ICIs) have improved outcomes, but response rates remain low and interindividual variability is substantial. The gut–liver–immune axis is proposed as a candidate modulator of this variability.
What the study showed
This is a narrative review; it generates no primary effect estimates. The review consolidates preclinical evidence that dysbiosis and bacterial translocation (e.g., Klebsiella pneumoniae via TLR4) promote hepatic inflammation, myeloid-derived suppressor cell expansion, and CD8+ T cell depletion. Experimental data show that FMT from HCC patients into germ-free mice reproduces hepatocarcinogenesis. No randomized clinical trial on microbiome intervention in HCC with ICI efficacy outcomes is reported.
How it was done
Narrative (non-systematic) review published in 2026. Integrates preclinical models (murine, germ-free), observational studies in other solid tumors, and emerging clinical data in HCC. No registered PRISMA protocol, explicit inclusion/exclusion criteria, or formal risk-of-bias assessment is provided.
Effect magnitude
No clinical effect estimate (RR, OR, HR, SMD) is derived directly from this review for human HCC interventions. Cited preclinical data come from animal models without validated quantitative extrapolation.
Risk of bias
Narrative review without systematic protocol (AMSTAR-2 not applicable): high risk of selection and confirmation bias. Clinical evidence in HCC is scarce and observational; most mechanistic data are preclinical. Heterogeneity across populations, HCC etiologies, and microbiome characterization methods limits conclusions.
What this study does NOT prove
This study does NOT prove that microbiome interventions improve ICI response or survival in HCC patients. It does NOT establish causality between microbiome composition and clinical immunotherapy efficacy in humans.
In clinical practice
No microbiome intervention (probiotics, FMT, diet) for modulating ICI response in HCC is supported by grade A or B clinical evidence. Clinicians should regard the gut–liver axis as an active research area, not an established therapeutic target. Predictive microbiome biomarkers for ICI response in HCC lack prospective validation.
Limitations
Narrative review without systematic protocol (AMSTAR-2 not applicable): high risk of selection and confirmation bias. Clinical evidence in HCC is scarce and observational; most mechanistic data are preclinical. Heterogeneity across populations, HCC etiologies, and microbiome characterization methods limits conclusions.
What is still missing
Randomized clinical trials evaluating microbiome interventions combined with ICIs in HCC, with overall survival and objective response rate endpoints. Prospective microbiome biomarker characterization studies in HCC are needed.
Technical appendix
Version history
- 1.0 · 2026-10-03 — Auto-generated under Evidence Standard v1.0